 The antiphospholipid-antibody syndrome APLA, which includes lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoproteinI antibodies, is a thrombophilic disorder associated with arterial thrombosis, venous thrombosis or both. Patients diagnosed with APLA have a higher risk of recurrent thrombosis than do patients without known antibodies. Currently, warfarin is considered the anticoagulant of choice for prophylactic antithrombotic treatment for APLA patients after their first episode of thrombosis. In some patients with APLA who are treated with warfarin, the INR values determined on plasma are unreliable due to an influence of the APLA on the INR. In these individuals, alternative monitoring methods, such as factor II activity, chromogenic factor X activity or prothrombin-proconvertin time should be used to assess adequate anticoagulation. These tests are expensive and not widely available to some clinicians. Point-of-care POC instruments, on the other hand, are readily accessible to clinicians. Previous research has shown that INR values from 3 older point-of-care POC instruments are unreliable in 13 of APLA patients CoaguChekTM, ProTimeTM, INRatioTM. However, there are now newer versions of these POC instruments available CoaguChek XSTM, an investigational ProTime device, and a newer INRatioTM device and it is unknown if these newer POC instruments are reliable in patients with APLA. The purpose of this study is to determine whether newer POC instruments are reliable in patients with APLA. 